Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.
Publication/Presentation Date
6-1-2020
Abstract
PURPOSE: Discordance between HER2 expression in tumor tissue (tHER2) and HER2 status on circulating tumor cells (cHER2) has been reported. It remains largely underexplored whether patients with tHER2
METHODS: cHER2 status was determined in 105 advanced-stage patients with tHER2
RESULTS: Compared to the patients with low-risk cHER2 (cHER2
CONCLUSION: In advanced-stage breast cancer patients with tHER2
Volume
181
Issue
3
First Page
679
Last Page
689
ISSN
1573-7217
Published In/Presented At
Wang, C., Mu, Z., Ye, Z., Zhang, Z., Abu-Khalaf, M. M., Silver, D. P., Palazzo, J. P., Jagannathan, G., Fellin, F. M., Bhattacharya, S., Jaslow, R. J., Tsangaris, T. N., Berger, A., Neupane, M., Cescon, T. P., Lopez, A., Yao, K., Chong, W., Lu, B., Myers, R. E., … Yang, H. (2020). Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. Breast cancer research and treatment, 181(3), 679–689. https://doi.org/10.1007/s10549-020-05662-x
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
32367460
Department(s)
Administration and Leadership
Document Type
Article